Table 3.

HRs (mutant/wild type) for death, according to treatment dose and gene

Gene	Mutant		Wildtype		Log-rank P	Univariate		Multivariable*
	Median OS (months) (no. of events/total)	4-year OS	Median OS (months) (no. of events/total)	4-year OS		HR (95% CI)	Wald P	No. of events/total	HR (95% CI)	Wald P
Main effect
NPM1	23.5 (81/130)	40%	16.9 (279/372)	29%	.01	0.73 (0.57, 0.94)	.01		0.68 (0.50, 0.92)	.01
FLT3-ITD	11.7 (118/147))	22%	25.0 (303/456))	38%	<.0001	1.65 (1.33, 2.04)	<.0001	338/477	1.67 (1.28, 2.19)	.0002
DNMT3A	15.3 (95/119)	23%	22.8 (254/371)	36%	.03	1.31 (1.03, 1.66)	.03	338/477338/477	1.54 (1.18, 2.01)	.002
MLL-PTD	16.9 (26/31)	19%	21.0 (405/586)	35%	.13	1.36 (0.92, 2.03)	.13	338/477	0.80 (0.49, 1.30)	.36
Standard dose
NPM1	16.9 (50/65)	29%	14.2 (148/180)	24%	.30	0.84 (0.61, 1.16)	.30	186/232	0.93 (0.63, 1.38)	.71
FLT3-ITD	10.1 (74/83)	17%	20.3 (156/215))	34%	<.0001	1.77 (1.34, 2.33)	<.0001	186/232	2.10 (1.45, 3.05)	<.0001
DNMT3A	14.1 (55/61)	13%	16.1 (137/177)	30%	.06	1.35 (0.98, 1.85)	.06	186/232	1.47 (1.03, 2.10)	.04
MLL-PTD	16.2 (16/16)	6%	16.5 (220/290)	30%	.08	1.58 (0.95, 2.63)	.08	186/232	1.01 (0.54, 1.90)	.98
High dose
NPM1	75.9 (31/65)	52%	23.3 (131/192)	34%	.01	0.60 (0.41, 0.89)	.01	152/245	0.48 (0.30, 0.78)	.003
FLT3-ITD	15.2 (44/64)	28%	31.7 (147/241)	42%	.04	1.43 (1.02, 2.01)	.04	152/245	1.35 (0.89, 2.04)	.16
DNMT3A	16.5 (40/58)	33%	29.2 (117/194)	41%	.23	1.25 (0.87, 1.79)	.23	152/245	1.51 (0.99, 2.31)	.06
MLL-PTD	20.6 (10/15)	33%	27.4 (185/296)	40%	.68	1.14 (0.61, 2.16)	.68	152/245	0.61 (0.27, 1.36)	.23

^*Sex, age, hemoglobin level, leukocyte count, platelet count, cytogenetics, and all 4 genes were fitted into the model.